ST. PAUL, Minn., May 24, 2017 /PRNewswire/ -- Cold sores, which affect one in three Americans, may be effectively treatedby a new immunotherapy process, as indicated by results of a 54-patient clinical trial at Massachusetts General Hospital in Boston.
The patented therapy was developed by Squarex, LLC, of St. Paul.
About a third of people world-wide
While further testing is underway to validate results, researchers say the clinical trial showed that a single topical application of the Squarex drug was significantly effective in reducing cold-sore recurrence for extended periods.
Patients in the clinical trial reported having at least six cold sore outbreaks over the previous 12 months before entering the clinical trial. After a single topical application of the drug, the time to next outbreak was tripled as compared to placebo: 40 days for the placebo group versus greater than 122 days for the group receiving the Squarex drug.
Dr. Maria Alora-Palli of Mass. General Hospital and Harvard Medical School is lead author of the scientific paper on the Squarex study, which appears in the current JAMA Dermatology.
Because the herpes simplex virus also causes genital herpes, Squarex President Dr. Hugh McTavish said his company would like to begin testing on the genital disease as well.
Squarex LLC is a privately held pharmaceutical development company. More at www.squarex-pharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cold-sore-treatment-developed-by-squarex-shown-effective-by-immunotherapy-study-300462263.html
SOURCE Squarex, LLC
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All